We firmly believe in the fact that the inhalation preparation is and will be the mainstream product in the market.
Our products will be approved in China and EU from year 2021 and on, and with a global sell, we will be a leading company in inhalation products and eyedrops soon.
Congratulations to Our Company on the Approval of a New Specification for Procaterol Hydrochloride Inhalation Solution, Including Pediatric Indications for Both Specifications
On September 24, 2024, our 0.3 mL specification of Procaterol Hydrochloride Inhalation Solution received production approval from the National Medical Products Administration (NMPA), alongside the 0.5 mL specification. Both specifications were approved for pediatric indications. Procaterol Hydrochloride Inhalation Solution is primarily used for the treatment of bronchial asthma, chronic bronchitis, and emphysema in both children and adults. The approval of this new specification not only expands Nanjing Aureole Pharmaceutical’ product line but also provides a more precise treatment option for pediatric patients with respiratory diseases.
Aureole Pharmaceutical is dedicated to the development of inhalation solutions and single-dose eye drops. The company remains focused on the research and development of innovative drugs to meet evolving market demands and improve patients’ quality of life.
Disclaimer:
1.This press release is intended to provide information on R&D registration progress and is for healthcare professionals only; it is not for promotional purposes.
2.Our company does not endorse any medication and/or indication.
3.The information contained in this press release is for reference only and does not substitute for professional medical advice. For specific diagnosis and treatment, please follow medical guidance.
